Sarepta Therapeutics, Inc. SRPT
The biggest changes in the 10-K filed Mar 2, 2026, in management's words
10-K, Item 7This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.
Operating margin
Big change, FY to Dec 31, 2025 vs Dec 31, 2024
The MD&A has no sentence that names a cause for this change.
Net income
Big change, FY to Dec 31, 2025 vs Dec 31, 2024
The MD&A has no sentence that names a cause for this change.
Revenue
Change, FY to Dec 31, 2025 vs Dec 31, 2024
“$72.1 million increase in deferred revenue primarily related to the timing of billings to Roche for orders of ELEVIDYS not yet shipped, partially offset by the recognition of collaboration revenue related to the expiration of an option for a certain program previously recorded as deferred revenue; and”
Read it in the 10-K
“$32.2 million decrease in deferred revenue primarily related to the collaboration with Roche.”
Read it in the 10-K
What management said, year by year
The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)
Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.
Revenue
2 of 2 years explained-
FY 2025 +4.3%
“$72.1 million increase in deferred revenue primarily related to the timing of billings to Roche for orders of ELEVIDYS not yet shipped, partially offset by the recognition of collaboration revenue related to the expiration of an option for a certain program previously recorded as deferred revenue; and”
Read it in the FY 2025 10-K“$32.2 million decrease in deferred revenue primarily related to the collaboration with Roche.”
Read it in the FY 2025 10-K -
FY 2024 +56.2%
“$32.2 million decrease in deferred revenue primarily related to the collaboration with Roche.”
Read it in the FY 2024 10-K“$86.8 million decrease in deferred revenue primarily related to the collaboration with Roche;”
Read it in the FY 2024 10-K
Operating margin
0 of 2 years explained-
FY 2025 -49.7 pts
The FY 2025 MD&A has no sentence that names a cause for this change.
-
FY 2024 +35.6 pts
The FY 2024 MD&A has no sentence that names a cause for this change.
Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K
Sources
The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.
Also
Financials: the numbers year by year.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SRPT/export.csv") into a cell.